Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer

被引:6
作者
Frantzi, Maria [1 ]
Gomez-Gomez, Enrique [2 ]
Mischak, Harald [1 ,3 ]
机构
[1] Mosa Diagnost GmbH, Dept Biomarker Res, Hannover, Germany
[2] Reina Sofia Univ Hosp, Urol Dept, Cordoba, Spain
[3] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland
来源
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT | 2020年 / 5卷 / 05期
关键词
Active surveillance; biomarkers; diagnosis; prostate cancer; treatment prediction; ESTRO-SIOG GUIDELINES; HEALTH INDEX; DNA METHYLATION; BLADDER-CANCER; SEMINAL PLASMA; URINE; ANTIGEN; MEN; PROGRESSION; BIOPSY;
D O I
10.1080/23808993.2020.1804866
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Prostate cancer (PCa) is one of the most frequently diagnosed malignancies worldwide and is associated with high mortality. Broad screening through prostate-specific antigen analysis, along with an aging and growing population has resulted in a vast increase in PCa incidence. As not all PCa forms are life threatening, personalized management is of paramount importance to preserve survival and quality of life for the diagnosed patients. Owing to the complexity of PCa, noninvasive biomarkers for diagnosis, stratification and monitoring, are essential to tailor intervention among patients with different disease manifestations. Areas covered: In this article, we aim to provide a critical assessment of the reported noninvasive biomarkers for PCa and their applicability according to the targeted clinical context. For this purpose, a systematic review of the literature published within the last five years was performed, focusing on noninvasive biomarkers to guide initial and repeated biopsies, stratify for active surveillance, monitor biochemical recurrence and metastasis, and adjust treatment for metastatic castration resistant PCa. Expert's opinion: Evidence from clinical trials on novel drugs and latest technological advancements, indicate several clinical applications for biomarkers to tailor intervention throughout PCa progression, toward a more personalized medicine approach in PCa clinical management.
引用
收藏
页码:383 / 400
页数:18
相关论文
共 112 条
[1]   Increased oncogenic microRNA-18a expression in the peripheral blood of patients with prostate cancer: A potential novel non-invasive biomarker [J].
Al-Kafaji, Ghada ;
Al-Naieb, Ziad Tariq ;
Bakhiet, Moiz .
ONCOLOGY LETTERS, 2016, 11 (02) :1201-1206
[2]   AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].
Antonarakis, Emmanuel S. ;
Lu, Changxue ;
Wang, Hao ;
Luber, Brandon ;
Nakazawa, Mary ;
Roeser, Jeffrey C. ;
Chen, Yan ;
Mohammad, Tabrez A. ;
Chen, Yidong ;
Fedor, Helen L. ;
Lotan, Tamara L. ;
Zheng, Qizhi ;
De Marzo, Angelo M. ;
Isaacs, John T. ;
Isaacs, William B. ;
Nadal, Rosa ;
Paller, Channing J. ;
Denmeade, Samuel R. ;
Carducci, Michael A. ;
Eisenberger, Mario A. ;
Luo, Jun .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038
[3]   PCA3 Molecular Urine Test for Predicting Repeat Prostate Biopsy Outcome in Populations at Risk: Validation in the Placebo Arm of the Dutasteride REDUCE Trial [J].
Aubin, Sheila M. J. ;
Reid, Jennifer ;
Sarno, Mark J. ;
Blase, Amy ;
Aussie, Jacqueline ;
Rittenhouse, Harry ;
Rittmaster, Roger ;
Andriole, Gerald L. ;
Groskopf, Jack .
JOURNAL OF UROLOGY, 2010, 184 (05) :1947-1952
[4]   Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis [J].
Barcelo, Maria ;
Castells, Manel ;
Bassas, Lluis ;
Vigues, Francesc ;
Larriba, Sara .
SCIENTIFIC REPORTS, 2019, 9 (1)
[5]   Prevalence of incidental prostate cancer: A systematic review of autopsy studies [J].
Bell, Katy J. L. ;
Del Mar, Chris ;
Wright, Gordon ;
Dickinson, James ;
Glasziou, Paul .
INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (07) :1749-1757
[6]   The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer [J].
Beltran, Himisha ;
Jendrisak, Adam ;
Landers, Mark ;
Mosquera, Juan Miguel ;
Kossai, Myriam ;
Louw, Jessica ;
Krupa, Rachel ;
Graf, Ryon P. ;
Schreiber, Nicole A. ;
Nanus, David M. ;
Tagawa, Scott T. ;
Marrinucci, Dena ;
Dittamore, Ryan ;
Scher, Howard I. .
CLINICAL CANCER RESEARCH, 2016, 22 (06) :1510-1519
[7]   A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort [J].
Braun, Katharina ;
Sjoberg, Daniel D. ;
Vickers, Andrew J. ;
Lilja, Hans ;
Bjartell, Anders S. .
EUROPEAN UROLOGY, 2016, 69 (03) :505-511
[8]  
Bryant RJ, 2015, JNCI-J NATL CANCER I, V107, P7
[9]   Early Detection of Prostate Cancer: AUA Guideline [J].
Carter, H. Ballentine ;
Albertsen, Peter C. ;
Barry, Michael J. ;
Etzioni, Ruth ;
Freedland, Stephen J. ;
Greene, Kirsten Lynn ;
Holmberg, Lars ;
Kantoff, Philip ;
Konety, Badrinath R. ;
Murad, Mohammad Hassan ;
Penson, David F. ;
Zietman, Anthony L. .
JOURNAL OF UROLOGY, 2013, 190 (02) :419-426
[10]   A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range [J].
Catalona, William J. ;
Partin, Alan W. ;
Sanda, Martin G. ;
Wei, John T. ;
Klee, George G. ;
Bangma, Chris H. ;
Slawin, Kevin M. ;
Marks, Leonard S. ;
Loeb, Stacy ;
Broyles, Dennis L. ;
Shin, Sanghyuk S. ;
Cruz, Amabelle B. ;
Chan, Daniel W. ;
Sokoll, Lori J. ;
Roberts, William L. ;
van Schaik, Ron H. N. ;
Mizrahi, Isaac A. .
JOURNAL OF UROLOGY, 2011, 185 (05) :1650-1655